Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide +/- WBRT in Melanoma Brain Metastases
NCT00020839Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2001
- Primary completion
- May 2003
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of temozolomide in melanoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall Survival. Started Apr 2001; status: terminated.
02
Drugs
temozolomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00020839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020839.